Lamisil and Psoriasis - a phase IV clinical study of FDA data

Summary:

Psoriasis is found among people who take Lamisil, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Lamisil and have Psoriasis. It is created by eHealthMe based on reports of 13,046 people who have side effects when taking Lamisil from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 04, 2022

13,046 people reported to have side effects when taking Lamisil.
Among them, 118 people (0.9%) have Psoriasis.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 13,647 Lamisil users for its effectiveness, alternative drugs and more.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 2,272 drugs and 1,581 conditions by eHealthMe.

Number of Lamisil and Psoriasis reports submitted per year:

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and have Psoriasis?

Check whether Psoriasis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

Related studies

How severe was Psoriasis and when was it recovered:

Psoriasis in Lamisil

Expand to all the drugs that have ingredients of terbinafine hydrochloride:

Psoriasis and drugs with ingredients of terbinafine hydrochloride (207 reports)

Alternative drugs to, pros and cons of Lamisil:

Lamisil (13,647 reports)

Common Lamisil side effects:

Rashes (redness): 916 reports
Itching: 743 reports
Fever: 646 reports
Fatigue (feeling of tiredness): 599 reports
Weight decreased: 568 reports

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Psoriasis treatments and more:

Psoriasis (412,216 reports)

COVID vaccines that are related to Psoriasis:

Common drugs associated with Psoriasis:

All the drugs that are associated with Psoriasis:

Psoriasis (2,272 drugs)

Common conditions associated with Psoriasis:

Rheumatoid arthritis: 6,377 reports
High blood pressure: 3,552 reports
Crohn's disease: 3,134 reports
Pain: 1,905 reports

All the conditions that are associated with Psoriasis:

Psoriasis (1,581 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.